Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab Biomarker Substudy in Untreated Multiple Myeloma
NCT01891643Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2013
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma Cells. Started Sep 2013; status: terminated.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01891643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891643.